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Eclampsia contributes significantly to
maternal and perinatal morbidity and mortality in
Nigeria. The world Health Organisation
recommended Magnesium Sulphate as the most
effective, safe and low cost drug for the treatment
of eclamptic seizures and for prophylaxis in severe
pre-eclamptic.This study is aimed to evaluate the
effect of the introduction of magnesium sulphate
for the management of eclamptic seizures on
maternal and fetal indices in Aminu Kano Teaching
Hospital [AKTH], Kano.
A retrospective study of all patients who
presented with eclampsia in AKTH, Kano. The study
period included 3years prior to introduction of
magnesium sulphate [January 2002- December
2004] and 3years after its introduction [January
2005 – December 2007].
During the study period, the prevalence of
eclampsia was1.02% [1: 97 deliveries]. Sixty six
[50.5%] of the patients were aged 19 and below.
Approximately 62% of the patients were
primigravida and 87% were unbooked. Thirty eight
[29%] were treated with diazepam while ninety
three[71%] were treated with magnesium
sulphate. 39.4% of those treated with diazepam
died compared to 15% of those treated with
magnesium sulphate. Approximately ninety
percent of those that died had no antenatal care.
Overall perinatal mortality rate in this study was
312 per 1000 births [41]. 368.4per 1000 births
among those treated with diazepam and296.7 per
1000births in the magnesium sulphate group.
Approximately nine percent of those treated with
magnesium sulphate develop toxicity [85.5% renal
and12% respiratory]
This study is in support of the findings
that magnesium sulphate is superior to diazepam
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Introduction
Eclampsia is a common cause of maternal
mortality worldwide but particularly in the
developing countries. It is estimated that every
year eclampsia is associated with about 50,000
maternal deaths worldwide, most of which occur
in developing countries . Nigeria has one of the
highest rates of maternal mortality in the world.
Eclampsia has been noted to be among the
commonest causes of maternal mortality in
Nigeria. The review of maternal deaths in Kano
state for example showed that eclampsia was the
commonest cause of the deaths and contributed
46.3% of all the maternal deaths in one study and
31.3% in another . In Birnin Kudu, in neighbouring
Jigawa state, eclampsia contributed 43.1% of all
maternal deaths .
In 1995, the Magpie trial was conducted. It was a
randomized, placebo-controlled study that
enrolled over 10,000 women in 33 countries
(including Nigeria) and across a wide variety of
clinical settings that confirmed the efficacy of
MgSO in the treatment of severe preeclampsia
and eclampsia. Women treated with MgSO had a
52% and 67% lower recurrence of convulsions
than those treated with diazepam and phenytoin,
respectively . Use of MgSO in patients with
severe preeclampsia reduced the risk of
progression to eclampsia by more than half and
reduced maternal mortality .
On the basis of the available evidence, The World
Health Organisation (WHO) has recommended
MgSO as the most effective, safe and low cost
drug for the treatment of severe preeclampsia
and eclampsia.
Magnesium sulphate was introduced for the
treatment of severe preeclampsia and eclampsia
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The Zuspan regimen (in which the maintenance
doses are given intravenously) is used for the
administration of the drug. This study was
conducted to evaluate the effect of the
introduction of the drug on maternal and fetal
indices.
The study was a retrospective study on consecutive
patients who presented to the hospital with
eclampsia. The period of the study included three
years prior to introduction of MgSO (January 2002
to December 2004) and three years after its
introduction (January 2005 to December 2007).
Case files were retrieved from medical records and
analyzed with EPI INFO VERSION 6.0 [CDC Atlanta
USA]. Chi Square test was used for comparison of
variables and p value <0.05 was considered as
significant. The outcomes measured were
maternal and perinatal mortality, APGAR scores at
1 and 5 minutes, toxic effects, delay at presentation
and booking for Antenatal care.
During the period of the study there were 15,888
deliveries and 163 eclamptic patients with a
prevalence of 1.02% (1:97 deliveries). However,
only 131 folders were retrieved (80% retrieval
rate). Sixty Six (50.3%) of the patients were aged 19
years and below. The mean parity was 2.2 but
majority were primigravida (61.6%). One hundred
and Fourteen (87%) were unbooked for antenatal
care.
The mean number of fits was 3.5 (range of 1-15).
There was demonstrable delay (inability to present
to the hospital within 6 hours of commencement of
fits) in 71 (54.2%) patients.
Thirty eight (29%) were treated with diazepam
while 93(71%) were treated with MgSO . Twenty
Nine (22.1%) of the mothers died.
Twenty five (35.2%) of those that delayed died
compared to 4(6.7%) of those that did not delay.
Delay associated with mortality (p<0.05). Of those
that died, 26(89.7%) did not have ANC as
compared to 3(10.3%) that had ANC. This was
statistically significant (p <0.05). Also, 15 (39.4%) of
the patients treated with diazepam died compared
to 14(15%) of the patients treated with MgSO . This






Fourty-one[31.2%] babies were delivered dead,
giving overall perinatal mortality rate of 312 per
1000births.the perinatal mortality rate among
those treated with diazepam was368.4 per 1000
births and 296.7 per 1000 births in those treated
with magnesium sulphate. This finding is not
statistically significant [p>0.05]. As shown in
figure 2.
Apgar score of six or less at one minute was 80.2%
in magnesium sulphate group compared to 94.7%
in diazepam group. While at five minute, it was
46.2% compared to 57.9%.
Eight patients who had magnesium sulphate
treatment had toxicity. Seven of these were renal
while one was respiratory.
The prevalence of eclampsia in this study was
1.02% [1 in 97 deliveries] , this is similar to the
finding in Ile –Ife [0.76%] but lower than 9.42%
reported from Birnin- Kudu.
Approximately 51% of the patients were aged
19years and below, this is comparable to 54%
reported in a similar study from Pakistan. Mean
parity of the patients was 2.2, but the majority of
the patients [61.6%] were primigravida, as was
reported by Abdul MA etal in Azare in a similar
study. This is largely because pre eclampsia and
eclampsia are diseases of the primigravida.
Eighty seven percent of the patients were
unbooked for antenatal care; this is similar to 84%
reported by other workers . This may be due to
poor public enlightenment on the importance of
antenatal care or aversion to western oriented
programs in the developing countries.
Eclampsia continues to be a significant cause of
serious morbidity and it is still one of the leading
triad of causes of maternal mortality in addition
to obstetric haemorrhage and sepsis. However
this study showed that maternal death is less
likely to develop in patients treated with
magnesium sulphate as compared to diazepam. It
was found that only 15% of those treated with
magnesium sulphate died compared to 39.4% of
those treated who had diazepam treatment. This
finding was in support of the Cochrane review,
which reported that magnesium sulphate is
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when compared to diazepam. this finding was
also reported by Ola EA etal in Lagos. Among those
that died only 10.3% had antenatal care while
89.7% had no such care. This showed that
antenatal care significantly influence maternal
death from eclampsia [p<0.05]. This could be due
to early hospital presentation for management
among the booked patients. Delay before hospital
presentation was found to be significantly
associated with mortality, because in this study,
35.2% of those who delayed before presentation
died compared to 6.7% of those that did not delay.
Overall, there were Fourty- one perinatal death in
this study, giving a perinatal mortality rate of
312/1000 births. The perinatal mortality rate for
those who had magnesium sulphate was
276.2/1000 births, while those who had diazepam
treatment had a perinatal mortality rate of
368.4/1000 births. This however was not
statistically significant [P >0.05]. This is comparable
to a similar study in Nepal.
There were also fewer infants with Apgar scores of
less than six [6] at one minute among those who
had magnesium sulphate therapy compared to






He reported that there were significantly fewer
infants born in the magnesium sulphate group
with low Apgar score [less than 7 atone minute]
compared with those in the diazepam group.
Eight patients [8-6%] who had magnesium
sulphate developed toxicity, seven of these were
renal and one was respiratory. This however is
significantly lower than 32% reported by Lee W
etal in a similar study.
This study showed that magnesium sulphate has
advantages over diazepam for the mother in the
management of eclampsia, as reported in other
studies ; however the benefit to the infant was
not statistically significant.
In conclusion ,this study confirm that eclampsia is
still a major cause of perinatal and maternal
mortality in our environment, therefore
considering the efficacy and safety of magnesium
sulphate, it is advocated that it should be made
widely available and its use be popularized in our
hospitals nation wide. There is need for
community health education for women to avail
them selves of antenatal care and skilled care
during delivery. Obstacle that impedes access to
health care should be removed. There is also need
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